Diacerein as a disease-modulating agent in osteoarthritis.
G Falgarone, M Dougados
Index: Curr. Rheumatol. Rep. 3(6) , 479-83, (2001)
Full Text: HTML
Abstract
This paper reviews the most recent clinical and experimental studies on diacerein, both of which are under investigation. Diacerein could be a disease-modulating agent in osteoarthritis because structural benefits have been reported in recent trials. Moreover, after an empirical use, studies return to the experimental field to understand the mechanism of action of this molecule. However, clinical trials using new sets of criteria could be conducted to estimate the structural modulating effect of diacerein; experimental studies must be performed to understand this effect.
Related Compounds
Related Articles:
1986-06-01
[Ann. Ital. Med. Int. 1(2) , 172-4, (1986)]
[Efficacy of diacerein on the symptoms and radiographic progression of osteoarthritis].
2002-12-07
[Presse Med. 31(39 Pt 2) , 4S13-5, (2002)]
1997-01-01
[Drugs 53(1) , 98-106; discussion 107-8, (1997)]
Clinical pharmacokinetics of diacerein.
1998-11-01
[Clin. Pharmacokinet. 35(5) , 347-59, (1998)]
Effects of diacerein on biosynthesis activities of chondrocytes in culture.
2000-01-01
[Biorheology 37(1-2) , 177-84, (2000)]